Phase I study of E-2814 in Alzheimer's disease/dementia.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2018
At a glance
- Drugs E 2814 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions
- 07 Dec 2018 According to an Eisai Co Ltd media release, this trial is expected to be initiated in early 2019.
- 06 Dec 2018 According to an Eisai Co Ltd media release, the company and University College London (UCL) have commenced preparations for this study. The study expects to commence within fiscal 2018.
- 19 Jun 2018 New trial record